Ascendis Pharma A/S | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (23)

View All

Latest Posts

About This Stock More About This Stock
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Article By: Zacks Investment Research
Saturday, March 9, 2024 4:00 PM EDT
Things have been looking better for the biotech industry in 2024 after a decent performance in 2023. Here is a look at some biotech stocks that may provide stability to one's portfolio throughout the year.
In this article: EXEL, EXAS, ASND, LEGN, MOR
Read
The Week Ahead In Biotech: Urogen FDA Decision, Amarin, J&J Earnings And More COVID-19 Updates
Article By: Benzinga
Sunday, April 12, 2020 1:22 PM EDT
Biotech stocks moved higher last week along with the broader market. The week witnessed a few clinical readouts and pre-announcements that reflected the coronavirus (COVID-19) impact.
In this article: ABT, JNJ, ALNY, GILD, ISRG, AMRN, AXSM, SCYX, ASND, URGN, ITRM, OVID, VIR
Read
Healthcare And Biotechs Feel The Heat As The Market At New Highs
Article By: Tarun Chandra, CFA
Wednesday, May 1, 2019 12:14 PM EDT
The stock market has continued to edge higher and the two major indexes, the Nasdaq (QQQ) and S&P 500 (SPY​), touched the all-time high milestone last week.
In this article: ACAD, ALXN, ARRY, AMRN, ARWR, AXSM, ASND
Read
Best Stock Pick From The 2018 Sohn Conference
Article By: Insider Monkey
Saturday, April 20, 2019 4:24 PM EDT
Stocks pitched at investment conferences aren’t necessarily the “best” stock picks of hedge funds as they sell them stocks afterward to create room for their real best ideas. However, these stocks still outperformed the market by an average of 7%.
In this article: AGO, BOX, BTU, CVS, DHI, HTZZ, MCK, TSLA, XOP, META, PANW, GRUB, ASND
Read
Week In Review: BioMérieux Acquires Majority Stake In China Diagnostics Company For $114 Million
Article By: ChinaBio® Today
Saturday, November 10, 2018 4:08 PM EDT
French in vitro diagnostics company, bioMérieux (Paris: BIM), acquired a majority stake in Suzhou Hybiome Biomedical Engineering for $114 million. Hybiome specializes in automated immunoassay tests.
In this article: ASND, EYPT
Read
All Posts

Latest Tweets for $ASND

No tweets yet!

PARTNER HEADLINES